Etavopivat Reduces Incidence of Vaso-occlusive Crises inPatients With Sickle Cell Disease: Hibiscus Trial Phase 2 Results through 52 Weeks

Research
Written By Christine Briscoe

Authors:Adam Wufsus, Sophia Delicou, Fuad El Rassi, Biree Andemariam, Miguel R. Abboud, Julie Kanter, Marilyn J. Telen, Jessie Githanga, Adlette Inati, Ibrahim M. Idris, Sunil Navani, Eric Wu, Andrew Eisenberger

Published June 6, 2025

Christine Briscoe
Next

Initial evaluation of an intervention to address provider implicit bias in pediatric sickle cell disease pain care: A mixed methods pilot study